Advertisement

Cancer Causes & Control

, Volume 20, Issue 2, pp 193–199 | Cite as

Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case–control study

  • Maria Dalamaga
  • Konstantinos Karmaniolas
  • Anna Panagiotou
  • Alex Hsi
  • John Chamberland
  • Cleanthi Dimas
  • Antigoni Lekka
  • Christos S. Mantzoros
Original Paper

Abstract

Accumulating evidence supports a role for obesity in the etiology of multiple myeloma (MM). The distinct possibility exists that obesity may be linked to MM through altered adipokine secretion and circulating levels, one of which, adiponectin, has a protective role in several malignancies, including leukemia. In this case–control study, we investigated the role of serum adiponectin, resistin, and leptin levels in the etiopathogenesis of MM and we explored their association with several established prognostic factors. Seventy three patients with incident, histologically confirmed MM and 73 controls matched on gender and age were studied between 2001 and 2007, and blood samples were collected. Serum adiponectin, leptin, resistin, as well as MM prognostic parameters were determined. Statistical analysis of the data was performed using univariate and multivariate analyses. Lower serum adiponectin and resistin levels were associated with higher risk of MM by bivariate analysis and after adjusting for age, gender, BMI, and serum levels of leptin (p < 0.0001). Adiponectin may have a protective role in MM, whereas leptin was not associated with risk for MM at a comparable level of significance and resistin levels may be decreased via a compensatory mechanism. Further studies are needed to confirm these associations and to explore the mechanisms underlying adiponectin’s role in MM and plasma cell dyscrasias.

Keywords

Adiponectin Leptin Resistin Adipokine Multiple myeloma 

Notes

Acknowledgment

This study was supported by a discretionary grant from BIDMC.

References

  1. 1.
    Foerster J, Paraskevas F (1998) Multiple myeloma. In: Lee GR, Foerster J, Luken J, Paraskevas F, Greer JP, Rodgers GM, Wintrobe MM (eds) Wintrobe’s clinical hematology, vol 2. Lippincott Williams & Wilkins, Baltimore, pp 2631–2655Google Scholar
  2. 2.
    Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860–1873. doi: 10.1056/NEJMra041875 PubMedCrossRefGoogle Scholar
  3. 3.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  4. 4.
    Lewis DR, Pottern LM, Brown LM, Silverman DT, Hayes RB, Schoenberg JB, Greenberg RS, Swanson GM, Schwartz AG, Liff JM (1994) Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation. Cancer Causes Control 5:529–539. doi: 10.1007/BF01831381 PubMedCrossRefGoogle Scholar
  5. 5.
    Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, Trichopoulos D (2007) Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 120:40–61. doi: 10.1002/ijc.22718 PubMedCrossRefGoogle Scholar
  6. 6.
    Morgan GJ, Davies FE, Linet M (2002) Myeloma aetiology and epidemiology. Biomed Pharmacother 56:223–234. doi: 10.1016/S0753-3322(02)00194-4 PubMedCrossRefGoogle Scholar
  7. 7.
    Bourguet CC, Logue EE (1993) Antigenic stimulation and multiple myeloma. A prospective study. Cancer 72:2148–2154. doi :10.1002/1097-0142(19931001)72:7<2148::AID-CNCR2820720714>3.0.CO;2-QPubMedCrossRefGoogle Scholar
  8. 8.
    Blair CK, Cerhan JR, Folsom AR, Ross JA (2005) Anthropometric characteristics and risk of multiple myeloma. Epidemiology 16:691–694. doi: 10.1097/01.ede.0000172135.61188.2d PubMedCrossRefGoogle Scholar
  9. 9.
    Birmann BM, Giovanucci E, Rosner B, Andesrson KC, Colditz GA (2007) Body mass index, physical activity and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 16:1474–1478. doi: 10.1158/1055-9965.EPI-07-0143 PubMedCrossRefGoogle Scholar
  10. 10.
    Chiu BC, Gapstur SM, Greenland P, Wang R, Dyer A (2006) Body mass index, abnormal glucose metabolism and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 15:2348–2354. doi: 10.1158/1055-9965.EPI-06-0007 PubMedCrossRefGoogle Scholar
  11. 11.
    Larsson SC, Wolk A (2007) Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer 121:2512–2516. doi: 10.1002/ijc.22968 PubMedCrossRefGoogle Scholar
  12. 12.
    Chan JL, Moschos SJ, Bullen J, Heist K, Li X, Kim YB, Kahn BB, Mantzoros CS (2005) Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 90:1625–1631. doi: 10.1210/jc.2004-1823 PubMedCrossRefGoogle Scholar
  13. 13.
    Matarese G, Moschos S, Mantzoros CS (2005) Leptin in immunology. J Immunol 174:3137–3142PubMedGoogle Scholar
  14. 14.
    Brennan AM, Mantzoros CS (2006) Drug Insight: the role of leptin in human physiology and pathophysiology-emerging clinical applications. Nat Clin Pract Endocrinol Metab 2:318–327. doi: 10.1038/ncpendmet0196 PubMedCrossRefGoogle Scholar
  15. 15.
    Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556. doi: 10.1210/jc.2004-0395 PubMedCrossRefGoogle Scholar
  16. 16.
    Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102–1107. doi: 10.1210/jc.2003-031804 PubMedCrossRefGoogle Scholar
  17. 17.
    Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89:1160–1163. doi: 10.1210/jc.2003-031716 PubMedCrossRefGoogle Scholar
  18. 18.
    Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S (2005) Prostate cancer and adiponectin. Urology 65:1168–1172. doi: 10.1016/j.urology.2004.12.053 PubMedCrossRefGoogle Scholar
  19. 19.
    Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H (2005) Plasma adiponectin and gastric cancer. Clin Cancer Res 11:466–472. doi: 10.1158/1078-0432.CCR-04-1453 PubMedCrossRefGoogle Scholar
  20. 20.
    Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS (2007) Low adiponectin levels are associated with renal cell carcinoma: a case–control study. Int J Cancer 120:1573–1578. doi: 10.1002/ijc.22526 PubMedCrossRefGoogle Scholar
  21. 21.
    Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688–1694PubMedCrossRefGoogle Scholar
  22. 22.
    Mantzoros CS, Trakatelli M, Gogas H, Dessypris N, Stratigos A, Chrousos GP, Petridou ET (2007) Circulating adiponectin levels in relation to melanoma: a case–control study. Eur J Cancer 43:1430–1436. doi: 10.1016/j.ejca.2007.03.026 PubMedCrossRefGoogle Scholar
  23. 23.
    Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D (2006) Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 94:156–160. doi: 10.1038/sj.bjc.6602896 PubMedCrossRefGoogle Scholar
  24. 24.
    Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88:4848–4856. doi: 10.1210/jc.2003-030519 PubMedCrossRefGoogle Scholar
  25. 25.
    Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O (2006) Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 28:241–244PubMedGoogle Scholar
  26. 26.
    Alexandrakis MG, Passam FH, Sfiridaki A, Pappa CA, Moschandrea JA, Kandidakis E, Tsirakis G, Kyriakou DS (2004) Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers 19:52–57PubMedGoogle Scholar
  27. 27.
    Durie BGM (1986) Staging and kinetics of multiple myeloma. Semin Oncol 13:300–309PubMedGoogle Scholar
  28. 28.
    Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842–854. doi :10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-UPubMedCrossRefGoogle Scholar
  29. 29.
    SAS/STAT User’s Guide (1989) NC, Cary. Ref Type: Computer ProgramGoogle Scholar
  30. 30.
    Lauta VM (2003) A review of the cytokine network in multiple myeloma: diagnostic, prognostic and therapeutic implications. Cancer 97:2440–2452. doi: 10.1002/cncr.11072 PubMedCrossRefGoogle Scholar
  31. 31.
    Ajuwon KM, Spurlock ME (2005) Adiponectin inhibits LPS-induced NF-kB activation and IL-6 production and increases PPARγ2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 288:1220–1225. doi: 10.1152/ajpregu.00397.2004 Google Scholar
  32. 32.
    Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME (2004) Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 316:924–929. doi: 10.1016/j.bbrc.2004.02.130 PubMedCrossRefGoogle Scholar
  33. 33.
    Nakao T, Hino M, Yamane T, Nishizawa Y, Morii H, Tatsumi N (1998) Expression of the leptin receptor in human leukaemic blast cells. Br J Haematol 102:740–745. doi: 10.1046/j.1365-2141.1998.00843.x PubMedCrossRefGoogle Scholar
  34. 34.
    Chan JL, Matarese G, Shetty GK, Raciti P, Kelesidis I, Aufiero D, De Rosa V, Perna F, Fontana S, Mantzoros CS (2006) Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci USA 103:8481–8486. doi: 10.1073/pnas.0505429103 PubMedCrossRefGoogle Scholar
  35. 35.
    Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312. doi: 10.1038/35053000 PubMedCrossRefGoogle Scholar
  36. 36.
    Rajala MW, Obici S, Scherer PE, Rossetti L (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111:225–230PubMedGoogle Scholar
  37. 37.
    Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R (2004) Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314:415–419. doi: 10.1016/j.bbrc.2003.12.104 PubMedCrossRefGoogle Scholar
  38. 38.
    Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O’Rahilly S (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50:2199–2202. doi: 10.2337/diabetes.50.10.2199 PubMedCrossRefGoogle Scholar
  39. 39.
    Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932–939. doi: 10.1161/01.CIR.0000155620.10387.43 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Maria Dalamaga
    • 1
    • 2
  • Konstantinos Karmaniolas
    • 3
  • Anna Panagiotou
    • 1
  • Alex Hsi
    • 4
  • John Chamberland
    • 4
  • Cleanthi Dimas
    • 1
  • Antigoni Lekka
    • 2
  • Christos S. Mantzoros
    • 4
  1. 1.Department of Clinical Biochemistry, Medical SchoolUniversity of Athens, “Attikon”, General University HospitalAthensGreece
  2. 2.Department of Laboratory HematologyNIMTS General HospitalAthensGreece
  3. 3.Department of Internal Medicine-Hematology SectionNIMTS General HospitalAthensGreece
  4. 4.Division of Endocrinology, Diabetes and MetabolismBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations